FDA grants rare paediatric disease designation for Novimmune ’s HLH emapalumab treatment

Swiss biopharmaceutical company Novimmune has received rare paediatric disease designation for its lead drug emapalumab from the US Food and Drug Administration (FDA) to treat patients with primary haemophagocytic lymphohistiocytosis (HLH).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news